Deep Kukreti, MD
Family Medicine · Laurel, MDNPI 1275507550
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 49.5% of the total. Reporting peaked in 2021 at $1,370 and has fallen 97.4% since, to $35 in 2025.
Across 48 payments — averaging $50.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$438
- Novo Nordisk$403
- Lilly USA, LLC$156
- Amgen$126
- Exact Sciences$62
- plus $41 from 2 others
What the payments were for
- Consulting fees$1,20049%
- Food & beverage$1,22651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 1 | $1,200 |
| AbbVie(2 entities) | 21 | $438 |
| Novo Nordisk | 10 | $403 |
| Lilly USA, LLC | 4 | $156 |
| Amgen | 7 | $126 |
| Exact Sciences | 3 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Medtronic | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- MOUNJARO$105
- UBRELVY$104
- Tresiba$100
- Ozempic$100
How this compares
$2,426 in reported general payments places this provider in the 80th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $20,033 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $3,166 |
| Atorvastatin Calcium | 240 | $2,379 |
| Losartan Potassium | 104 | $1,088 |
| Amlodipine Besylate | 142 | $1,070 |
| Metformin Hcl | 112 | $1,010 |
| Metoprolol Succinate | 76 | $902 |
| Famotidine | 39 | $679 |
| Levothyroxine Sodium | 52 | $655 |
| Simvastatin | 74 | $641 |
| Hydrochlorothiazide | 113 | $638 |
| Gabapentin | 27 | $540 |
| Fluticasone Propionate | 29 | $519 |
| Lisinopril | 107 | $509 |
| Alendronate Sodium | 57 | $497 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Laurel
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
- Casey ScottCambridge$88K
- Daljeet SalujaBaltimore$63K
- Sanjay SaxenaHagerstown$60K
- Cynthia KleppingerSilver Spring$51K
- Tramaine DavisBowie$43K
- Alkesh PatelColumbia$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.